Business Context and Reporting Period
Company: Fulgent Genetics, Inc. (FLGT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Fulgent operates two primary segments: a well-established laboratory services business offering precision diagnostics and anatomic pathology, and a therapeutic development business (Fulgent Pharma) focused on nanoencapsulation technology for cancer treatments. The company aims to transform into a fully integrated precision medicine company.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $322.7 million | $283.5 million | +14% |
| Gross Profit | $130.9 million | $107.2 million | +22% |
| Gross Margin | 41.0% | 38.0% | +300 bps |
| Operating Loss | ($91.1 million) | ($73.9 million) | -23% |
| Net Loss (Attributable to Fulgent) | ($60.5 million) | ($42.7 million) | -42% |
| Cash & Marketable Securities | $705.5 million | $828.6 million | -15% |
| Operating Cash Flow | ($101.6 million) | $21.1 million | Significant Decline |
| Debt (Notes Payable) | $2.4 million | $2.9 million | -17% |
Note: Operating cash flow turned negative primarily due to a $99.5 million cash purchase of Investment Tax Credits (ITCs).
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 14% increase in precision diagnostics (reproductive health and legacy offerings), a 10% increase in anatomic pathology, and a 55% surge in BioPharma services. COVID-19 revenue ceased to be material.
- Expense Increases: General and Administrative (G&A) expenses rose 32% to $116.7 million, largely due to a $14.5 million accrual for a professional liability settlement and a $9.4 million provision for credit losses. R&D expenses increased 10% to $53.9 million, driven by clinical trial advancements for FID-007 and FID-022.
- Customer Concentration: One customer accounted for 22% ($70.8 million) of total revenue in 2025. Management noted lower-than-anticipated volume from this customer in Q4 2025 and expects reduced revenue from them in 2026 as they internalize certain testing services.
- Acquisitions: Completed the acquisition of ANP Technologies, Inc. in July 2025 to secure full ownership of patents for therapeutic candidates. Announced definitive agreements in December 2025 to acquire Bako Diagnostics and StrataDx for approximately $55.5 million (expected to close in H1 2026).
Guidance, Outlook, and Risks
- Therapeutic Pipeline:
- FID-007: Phase 2 enrollment completed for Head & Neck cancer; interim findings expected June 2026. Phase 3 initiation targeted for H1 2027.
- FID-022: Phase 1/1b trial ongoing; third dose level commenced February 2026.
- Regulatory Environment: The FDA's final rule on Laboratory Developed Tests (LDTs) was vacated by a federal court in March 2025, removing immediate regulatory burdens. However, uncertainty remains regarding future legislative frameworks. The company received CE certification under the EU IVDR for its germline NGS system in July 2025.
- Government Investigations: The company is cooperating with an ongoing HRSA audit regarding COVID-19 reimbursements (approx. $548.9 million received historically) and Civil Investigative Demands (CIDs) from the DOJ regarding billing practices. No liability has been recorded as the outcome is uncertain.
- Liquidity: Management expects existing cash and marketable securities ($705.5 million) to be sufficient for at least the next 12 months. The company maintains a $139.6 million remaining capacity under its stock repurchase program.
Investor Verification Checklist
- Customer Concentration Risk: Verify the extent of revenue decline from the single customer representing 22% of revenue and the success of diversification efforts in 2026.
- Government Audit Outcomes: Monitor the resolution of the HRSA audit and DOJ CIDs regarding COVID-19 billing, which could result in significant refunds or penalties.
- Professional Liability Settlement: Confirm the final payout amount and insurance recovery status for the $14.5 million liability accrual.
- Acquisition Integration: Track the closing timeline and integration progress of the Bako Diagnostics and StrataDx acquisitions announced in December 2025.
- Clinical Trial Milestones: Watch for the interim data readout for FID-007 in June 2026, which is critical for the therapeutic segment's valuation.